Method for formulating healthcare products with enhanced stability
A method is disclosed for formulating healthcare products, including solid pharmaceutical compositions, while avoiding instability caused ba interaction of the active ingredient with excipients. The method comprises the steps of: (a) selecting an active ingredient that loses stability or potency upon interaction with pharmaceutical excipients; and (b) depositing the active ingredient, preferably electrostatically, as a dry powder substantially free of excipients, onto a pharmaceutically acceptable polymer substrate.
1 . A method of formulating a healthcare product while avoiding instability caused by interaction of the active ingredient with excipients, the method comprising:
(a) selecting an active ingredient that loses stability or potency upon interaction with pharmaceutical excipients; and
(b) depositing the active ingredient, as a dry powder substantially free of excipients, onto a pharmaceutically acceptable polymer substrate.
2 . The method of claim 1 , wherein the depositing is performed electrostatically.
3 . The method of claim 2 , wherein the healthcare product is a solid pharmaceutical dosage.
4 . The method of claim 1 , wherein the polymer has received regulatory approval and is of GRAS status.
5 . The method of claim 4 , wherein the polymer is selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidinone, polysaccharide polymers, acrylate polymers, methacrylate polymers, phthalate polymers, polyvinyl acetate, methyl cellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ethyl cellulose, Eudragits, starch-based polymers, gelatin, and combinations thereof.
6 . The method of claim 3 , wherein the active ingredient is selected from the group consisting of lansoprazole, molsidomime, topotecan, moexipril, oxprenolol, Astra FLA 336, nifedipine, steroids, nitroglycerine, heparin, insulin and drugs of biological origin.
7 . The method of claim 3 , further comprising:
(a) applying a cover film to encapsulate the electrostatically deposited active ingredient, so as to form a stable core; and
(b) further processing the stable core into a dosage form resembling a tablet, capsule, caplet, wafer or stamp-like presentation.
8 . An improved solid pharmaceutical dosage formulation, comprising a therapeutic amount of an active pharmaceutical ingredient, deposited on a pharmaceutically acceptable polymer substrate as a dry powder substantially free of excipients.
9 . The formulation of claim 8 , wherein the active ingredient is deposited electrostatically.